Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Ad5-survivin-transduced autologous DC vaccine + Filgrastim + PCV13 vaccine |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Ad5-survivin-transduced autologous DC vaccine | Autologous DC:AdmS | Ad5-survivin-transduced autologous DC vaccine consists of autologous dendritic cells engineered to carry a replication defective adenovirus type 5 vector (Ad5) that encodes a survivin antigen, which potentially activates a cytotoxic T-lymphocyte response against survivin-expressing tumor cells, resulting in cell death (NCI Drug Dictionary). | ||
Filgrastim | Neupogen | G-CSF | Neupogen (filgrastim) is a recombinant analog of granulocyte colony-stimulating factor (G-CSF) isoform B, which binds and activates G-CSF receptors modulating neutrophilic granulocyte progenitor activity, production, and differentiation (NCI Drug Dictionary). | |
PCV13 vaccine | PCV 13|Prevnar 13 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02851056 | Phase I | Ad5-survivin-transduced autologous DC vaccine + Filgrastim + PCV13 vaccine | Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT) | Completed | USA | 0 |